APA (7th ed.) Citation

Silva, D., Doi, T., Koganemaru, S., Thistlethwaite, F., Zair, Z., Yamamoto, N., . . . Banerji, U. (2025). 1520MO Phase I first-in-human study of a novel anti-CD137 switch antibody agonist STA551 (STA) as monotherapy and in combination with atezolizumab (atezo) in patients (pts) with advanced solid tumors. Annals of Oncology, 36, S911. https://doi.org/10.1016/j.annonc.2025.08.2151

Chicago Style (17th ed.) Citation

Silva, D., et al. "1520MO Phase I First-in-human Study of a Novel Anti-CD137 Switch Antibody Agonist STA551 (STA) as Monotherapy and in Combination with Atezolizumab (atezo) in Patients (pts) with Advanced Solid Tumors." Annals of Oncology 36 (2025): S911. https://doi.org/10.1016/j.annonc.2025.08.2151.

MLA (9th ed.) Citation

Silva, D., et al. "1520MO Phase I First-in-human Study of a Novel Anti-CD137 Switch Antibody Agonist STA551 (STA) as Monotherapy and in Combination with Atezolizumab (atezo) in Patients (pts) with Advanced Solid Tumors." Annals of Oncology, vol. 36, 2025, p. S911, https://doi.org/10.1016/j.annonc.2025.08.2151.